ArticleNPJ precision oncology2025
Optimized culturing yields high success rates and preserves molecular heterogeneity, enabling personalized screening for high-grade gliomas.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Modelling brain tumours with organoids: towards precision medicine in neuro-oncology.Nature reviews. Neurology · 2026Review
- Overcoming Chemoresistance in Glioblastoma: Mechanisms, Therapeutic Strategies, and Functional Precision Medicine.International journal of molecular sciences · 2026Review
- Bioengineering Stem Cell-Derived Glioblastoma Organoids: A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To discover new treatment options for high-grade glioma (HGG), robust in vitro models are essential, but reliably establishing patient-derived cell cultures remains challenging. We established glioma stem-like cell (GSC) cultures from 114 consecutive HGG specimens via traditional surgical resection and/or ultrasonic aspiration, using completely dissociated single cell (single cell-derived, SCD) and partially dissociated 3D-derived (3DD) tissue fragments. Higher success rates in culture establishment were obtained from ultrasonic aspirates and 3DD surgical samples. Combining these approaches yielded a 96% success rate. Copy number profiling showed overall genetic similarities between cultures and parental tissue. Single-cell sequencing revealed greater transcriptomic heterogeneity in ultrasonic aspiration-derived cultures. Our protocol enabled the screening of 20 anti-cancer agents within a clinically relevant timeframe for 16 out of 18 HGG samples. This refined protocol serves as a robust tool for establishing HGG cell cultures that retain the molecular characteristics of the tumors and support applications in precision medicine.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.